6-Mar-2026
PRNewswire (Mon, 2-Mar 9:10 AM ET)
PRNewswire (Mon, 23-Feb 8:55 AM ET)
PRNewswire (Mon, 9-Feb 8:00 AM ET)
PRNewswire (Mon, 2-Feb 9:00 AM ET)
PRNewswire (Tue, 27-Jan 8:30 AM ET)
Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
PRNewswire (Mon, 15-Dec 8:45 AM ET)
ANIX Advances Breast Cancer Vaccine After Phase 1 Data Shows 74% Immune Response Rate
Market Chameleon (Fri, 12-Dec 2:08 AM ET)
PRNewswire (Thu, 11-Dec 6:02 PM ET)
Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025
PRNewswire (Wed, 10-Dec 9:00 AM ET)
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Anixa Biosciences trades on the NASDAQ stock market under the symbol ANIX.
As of March 6, 2026, ANIX stock price declined to $2.85 with 87,184 million shares trading.
ANIX has a beta of 0.71, meaning it tends to be less sensitive to market movements. ANIX has a correlation of 0.04 to the broad based SPY ETF.
ANIX has a market cap of $95.12 million. This is considered a Micro Cap stock.
In the last 3 years, ANIX traded as high as $6.45 and as low as $2.07.
The top ETF exchange traded funds that ANIX belongs to (by Net Assets): VTI, VXF, IWC.
ANIX has underperformed the market in the last year with a return of -2.4%, while the SPY ETF gained +18.7%. In the last 3 month period, ANIX fell short of the market, returning -40.5%, while SPY returned -1.7%. However, in the most recent 2 weeks ANIX has outperformed the stock market by returning -1.0%, while SPY returned -2.5%.
ANIX support price is $2.76 and resistance is $3.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIX shares will trade within this expected range on the day.
